Role of Inflammation in Atrial Fibrillation Pathophysiology and Management
Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggest...
Saved in:
| Published in | Circulation Journal Vol. 79; no. 3; pp. 495 - 502 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japanese Circulation Society
2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. That evidence includes elevated serum levels of inflammatory biomarkers in AF subjects, the expression of inflammatory markers in cardiac tissues of AF patients and animal models of AF, and beneficial effects of anti-inflammatory drugs in experimental AF paradigms. Inflammation is suggested to be linked to various pathological processes, such as oxidative stress, apoptosis, and fibrosis, that promote AF substrate formation. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thrombogenesis. Thus, inflammation may contribute to both the occurrence/maintenance of AF and its thromboembolic complications. Here, we review the evidence for a role of inflammation and inflammatory biomarkers in the risk management and treatment of AF. We also summarize the current knowledge of inflammation-dependent cellular and molecular mechanisms in AF pathophysiology and their potential as therapeutic targets. (Circ J 2015; 79: 495–502) |
|---|---|
| AbstractList | Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. That evidence includes elevated serum levels of inflammatory biomarkers in AF subjects, the expression of inflammatory markers in cardiac tissues of AF patients and animal models of AF, and beneficial effects of anti-inflammatory drugs in experimental AF paradigms. Inflammation is suggested to be linked to various pathological processes, such as oxidative stress, apoptosis, and fibrosis, that promote AF substrate formation. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thrombogenesis. Thus, inflammation may contribute to both the occurrence/maintenance of AF and its thromboembolic complications. Here, we review the evidence for a role of inflammation and inflammatory biomarkers in the risk management and treatment of AF. We also summarize the current knowledge of inflammation-dependent cellular and molecular mechanisms in AF pathophysiology and their potential as therapeutic targets. (Circ J 2015; 79: 495–502) Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. That evidence includes elevated serum levels of inflammatory biomarkers in AF subjects, the expression of inflammatory markers in cardiac tissues of AF patients and animal models of AF, and beneficial effects of anti-inflammatory drugs in experimental AF paradigms. Inflammation is suggested to be linked to various pathological processes, such as oxidative stress, apoptosis, and fibrosis, that promote AF substrate formation. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thrombogenesis. Thus, inflammation may contribute to both the occurrence/maintenance of AF and its thromboembolic complications. Here, we review the evidence for a role of inflammation and inflammatory biomarkers in the risk management and treatment of AF. We also summarize the current knowledge of inflammation-dependent cellular and molecular mechanisms in AF pathophysiology and their potential as therapeutic targets. Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. That evidence includes elevated serum levels of inflammatory biomarkers in AF subjects, the expression of inflammatory markers in cardiac tissues of AF patients and animal models of AF, and beneficial effects of anti-inflammatory drugs in experimental AF paradigms. Inflammation is suggested to be linked to various pathological processes, such as oxidative stress, apoptosis, and fibrosis, that promote AF substrate formation. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thrombogenesis. Thus, inflammation may contribute to both the occurrence/maintenance of AF and its thromboembolic complications. Here, we review the evidence for a role of inflammation and inflammatory biomarkers in the risk management and treatment of AF. We also summarize the current knowledge of inflammation-dependent cellular and molecular mechanisms in AF pathophysiology and their potential as therapeutic targets.Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most important is thrombogenesis), as well as for assessing AF risk and underlying pathophysiology, are largely limited. Emerging evidence suggests a significant role of inflammation in the pathogenesis of AF. That evidence includes elevated serum levels of inflammatory biomarkers in AF subjects, the expression of inflammatory markers in cardiac tissues of AF patients and animal models of AF, and beneficial effects of anti-inflammatory drugs in experimental AF paradigms. Inflammation is suggested to be linked to various pathological processes, such as oxidative stress, apoptosis, and fibrosis, that promote AF substrate formation. Inflammation has also been associated with endothelial dysfunction, platelet activation, and coagulation cascade activation, leading to thrombogenesis. Thus, inflammation may contribute to both the occurrence/maintenance of AF and its thromboembolic complications. Here, we review the evidence for a role of inflammation and inflammatory biomarkers in the risk management and treatment of AF. We also summarize the current knowledge of inflammation-dependent cellular and molecular mechanisms in AF pathophysiology and their potential as therapeutic targets. |
| Author | Wagoner, David R. Van Harada, Masahide Nattel, Stanley |
| Author_xml | – sequence: 1 fullname: Nattel, Stanley organization: Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal – sequence: 1 fullname: Wagoner, David R. Van organization: Department of Molecular Cardiology, Cleveland Clinic – sequence: 1 fullname: Harada, Masahide organization: Department of Cardiology, Fujita Health University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25746525$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kclvEzEYxS1URBe4c0Jz5DLteB9fkKqI0EZFIARny-MlceSxg-0g5b9nsrQFDlxsy36_9-T3XYKzmKIF4C3sriGi-Eb7rNfXs0ULadtB3L8AFxAT3pIedWeHM2tFT_A5uCxl3XVIdFS8AueIcsIoohdg8S0F2yTX3EcX1Diq6lNsfGxua_YqNHM_ZB_C8fqrqqu0We2KTyEtd42Kpvmsolra0cb6Grx0KhT75rRfgR_zj99nd-3Dl0_3s9uHVjPOa8u0MYw5hKCBjlkoBqEtpL0ZCBcQG42QIZ0SlDHjeoRdj3sHqYOcDm4YHL4CH46-m-0wWqOn6KyC3GQ_qryTSXn590v0K7lMvyQhlGNGJoP3J4Ocfm5tqXL0Rdvpl9GmbZGQMSgEFYRP0nd_Zj2FPBY4CdhRoHMqJVsnta-HtqZoHyTs5H5S8jApOVtISOV-UhPY_QM-ev8HmR-RdalT50-AytXrYE8AFxLvl2fwWbBSWdqIfwOT8LLO |
| CitedBy_id | crossref_primary_10_1007_s13205_024_04024_4 crossref_primary_10_1371_journal_pone_0142937 crossref_primary_10_3389_fcvm_2021_674612 crossref_primary_10_1038_s41598_022_13773_2 crossref_primary_10_1080_14779072_2018_1510318 crossref_primary_10_1007_s10388_020_00804_y crossref_primary_10_3389_fcvm_2021_641136 crossref_primary_10_1186_s12967_019_02162_5 crossref_primary_10_1016_j_ejphar_2021_174622 crossref_primary_10_1161_JAHA_118_008842 crossref_primary_10_1016_j_arr_2020_101045 crossref_primary_10_1097_FJC_0000000000000313 crossref_primary_10_3390_ijms22073467 crossref_primary_10_1093_europace_euaa304 crossref_primary_10_1080_1354750X_2023_2284122 crossref_primary_10_1002_clc_23678 crossref_primary_10_1161_CIRCULATIONAHA_118_039461 crossref_primary_10_1016_j_hlc_2018_05_102 crossref_primary_10_1016_j_jocn_2022_05_018 crossref_primary_10_1002_joa3_12984 crossref_primary_10_1016_j_ccep_2020_10_006 crossref_primary_10_1177_0300060520921671 crossref_primary_10_3390_ijms25158407 crossref_primary_10_15829_1560_4071_2022_5098 crossref_primary_10_1007_s00424_022_02743_2 crossref_primary_10_3390_jcm13175088 crossref_primary_10_1161_JAHA_119_013133 crossref_primary_10_1007_s12265_020_09965_8 crossref_primary_10_1016_j_numecd_2021_05_034 crossref_primary_10_3390_biom12101542 crossref_primary_10_1016_j_ccep_2020_10_001 crossref_primary_10_4330_wjc_v17_i1_99933 crossref_primary_10_2174_1871529X19666190410145501 crossref_primary_10_1016_j_cpcardiol_2024_102699 crossref_primary_10_1590_1806_9282_66_6_800 crossref_primary_10_3389_fcvm_2022_1061243 crossref_primary_10_3390_brainsci10070420 crossref_primary_10_1080_14796678_2025_2458414 crossref_primary_10_3390_medicina58081053 crossref_primary_10_31146_1682_8658_ecg_170_10_26_32 crossref_primary_10_1186_s12263_022_00708_9 crossref_primary_10_1016_j_trsl_2019_10_002 crossref_primary_10_1111_bph_15417 crossref_primary_10_12677_acm_2024_1441386 crossref_primary_10_1111_pace_13368 crossref_primary_10_1016_j_echo_2017_03_014 crossref_primary_10_1016_j_jjcc_2019_05_018 crossref_primary_10_3389_fsurg_2022_1089930 crossref_primary_10_1016_j_cjca_2018_08_036 crossref_primary_10_3390_jcm12155034 crossref_primary_10_1016_j_jaad_2019_08_039 crossref_primary_10_1536_ihj_23_051 crossref_primary_10_3390_medicina55070358 crossref_primary_10_1016_j_ijcard_2021_07_051 crossref_primary_10_1093_europace_euv395 crossref_primary_10_1007_s00392_019_01512_z crossref_primary_10_2139_ssrn_4102637 crossref_primary_10_1186_s13019_024_02822_8 crossref_primary_10_1080_07853890_2018_1492147 crossref_primary_10_2174_1389450121666200302095103 crossref_primary_10_1097_MD_0000000000010132 crossref_primary_10_14814_phy2_12897 crossref_primary_10_1016_j_ijcrp_2023_200182 crossref_primary_10_1161_JAHA_118_008703 crossref_primary_10_1016_j_ijcard_2019_06_045 crossref_primary_10_1016_j_numecd_2019_06_021 crossref_primary_10_1093_cvr_cvab093 crossref_primary_10_2174_0929867324666170830100424 crossref_primary_10_1016_j_repc_2020_07_009 crossref_primary_10_1093_europace_euw131 crossref_primary_10_2174_1570161120666220831094507 crossref_primary_10_1016_j_rmed_2023_107508 crossref_primary_10_2147_VHRM_S463648 crossref_primary_10_3390_ijms21134655 crossref_primary_10_1016_j_ajem_2020_12_062 crossref_primary_10_1161_CIRCULATIONAHA_120_049768 crossref_primary_10_1007_s13410_022_01136_6 crossref_primary_10_1177_2042098617712657 crossref_primary_10_3892_mmr_2017_6477 crossref_primary_10_1136_bmjopen_2020_047642 crossref_primary_10_1016_j_heliyon_2022_e09161 crossref_primary_10_1080_17435390_2021_1917716 crossref_primary_10_1253_circrep_CR_24_0123 crossref_primary_10_1016_j_ijcard_2024_132393 crossref_primary_10_1080_00015385_2020_1858538 crossref_primary_10_1186_s12871_023_02281_z crossref_primary_10_1016_j_bbadis_2020_165757 crossref_primary_10_3390_ijms21165717 crossref_primary_10_1253_circj_CJ_15_1352 crossref_primary_10_2196_26519 crossref_primary_10_1016_j_ccep_2020_11_002 crossref_primary_10_1161_CIRCRESAHA_117_311081 crossref_primary_10_3390_jcm14010034 crossref_primary_10_1016_j_jacc_2015_07_003 crossref_primary_10_1111_sms_12830 crossref_primary_10_4103_cjhr_cjhr_81_19 crossref_primary_10_3390_ijms21082844 crossref_primary_10_1007_s10840_023_01690_x crossref_primary_10_1002_jcp_27968 crossref_primary_10_3389_fcvm_2024_1414974 crossref_primary_10_1002_joa3_12424 crossref_primary_10_1016_j_cjco_2022_12_012 crossref_primary_10_1111_joim_12748 crossref_primary_10_1097_NR9_0000000000000050 crossref_primary_10_1161_CIRCRESAHA_121_319425 crossref_primary_10_3390_ijms20092215 crossref_primary_10_1161_CIRCULATIONAHA_118_035202 crossref_primary_10_1055_s_0043_1776328 crossref_primary_10_3892_mmr_2024_13333 crossref_primary_10_1016_j_ijcard_2017_12_076 crossref_primary_10_1253_circj_CJ_16_0493 crossref_primary_10_31083_j_rcm2504127 crossref_primary_10_1016_j_athoracsur_2017_04_060 crossref_primary_10_2147_IJGM_S406926 crossref_primary_10_1080_08998280_2021_1951071 crossref_primary_10_1093_cvr_cvaa186 crossref_primary_10_3390_biom12050720 crossref_primary_10_1089_gtmb_2019_0142 crossref_primary_10_1016_j_trsl_2021_01_007 crossref_primary_10_1111_echo_13213 crossref_primary_10_1002_clc_22931 crossref_primary_10_1155_2020_6569728 crossref_primary_10_3390_ijerph21020129 crossref_primary_10_1253_circj_CJ_17_1194 crossref_primary_10_12677_ACM_2023_1371582 crossref_primary_10_1016_j_jelectrocard_2020_04_014 crossref_primary_10_1177_1076029618761006 crossref_primary_10_3389_fcvm_2023_1110707 crossref_primary_10_1007_s10554_019_01597_7 crossref_primary_10_1016_j_trsl_2020_04_013 crossref_primary_10_20996_1819_6446_2020_10_21 crossref_primary_10_1038_s41569_022_00759_w crossref_primary_10_1007_s00380_017_1015_2 crossref_primary_10_1016_j_thromres_2022_03_009 crossref_primary_10_1016_j_xcrm_2022_100749 crossref_primary_10_1161_JAHA_120_018019 crossref_primary_10_1007_s00210_021_02115_0 crossref_primary_10_1016_j_heliyon_2023_e18818 crossref_primary_10_3390_nu16162672 crossref_primary_10_1016_j_bj_2024_100821 crossref_primary_10_1160_TH17_02_0130 crossref_primary_10_4049_jimmunol_1701090 crossref_primary_10_15829_1560_4071_2019_7_103_109 crossref_primary_10_1002_joa3_12684 crossref_primary_10_7554_eLife_67077 crossref_primary_10_29328_journal_jccm_1001196 crossref_primary_10_1016_j_ajem_2020_08_013 crossref_primary_10_1186_s12920_021_01124_5 crossref_primary_10_3389_fcvm_2021_779503 crossref_primary_10_1093_ehjqcco_qcx043 crossref_primary_10_1016_j_jcmg_2020_04_031 crossref_primary_10_12677_ACM_2021_1112908 crossref_primary_10_1038_s41598_017_02902_x crossref_primary_10_1371_journal_pone_0259652 crossref_primary_10_1093_cvr_cvw007 crossref_primary_10_1097_CRD_0000000000000426 crossref_primary_10_1111_anec_12566 crossref_primary_10_1002_ehf2_14089 crossref_primary_10_1371_journal_pone_0248644 crossref_primary_10_4103_ijd_IJD_69_17 crossref_primary_10_1016_j_jjcc_2016_12_013 crossref_primary_10_1111_jth_13441 crossref_primary_10_3390_jcm13164621 crossref_primary_10_3892_ijmm_2019_4416 crossref_primary_10_1016_j_jacep_2020_09_030 crossref_primary_10_1186_s12920_022_01300_1 crossref_primary_10_15829_1560_4071_2021_4307 crossref_primary_10_1111_jce_12680 crossref_primary_10_1186_s12872_023_03283_y crossref_primary_10_4103_aian_aian_62_24 crossref_primary_10_1093_ehjcvp_pvaa013 crossref_primary_10_18632_oncotarget_23783 crossref_primary_10_1016_j_ijcard_2021_09_047 crossref_primary_10_1161_JAHA_119_014059 crossref_primary_10_1111_jce_14987 crossref_primary_10_1080_00325481_2019_1608071 crossref_primary_10_1186_s13287_024_03814_0 crossref_primary_10_18501_arrhythmia_2017_028 crossref_primary_10_1016_j_hrthm_2019_03_017 crossref_primary_10_1186_s12872_023_03270_3 crossref_primary_10_5105_jse_40_75 crossref_primary_10_1016_j_neurot_2024_e00327 crossref_primary_10_1111_pace_13765 crossref_primary_10_1007_s00210_018_1566_5 crossref_primary_10_1536_ihj_19_680 crossref_primary_10_2147_JIR_S429892 crossref_primary_10_2174_0113894501267496231102114410 crossref_primary_10_3390_ijms232415946 crossref_primary_10_1007_s00380_021_01908_w crossref_primary_10_24207_jca_v32n4_111_PT crossref_primary_10_1016_j_ahjo_2025_100525 crossref_primary_10_1111_jcmm_14796 crossref_primary_10_1590_1516_3180_2018_0431140319 crossref_primary_10_1016_j_ijcard_2017_03_132 crossref_primary_10_1016_j_yjmcc_2019_01_012 crossref_primary_10_1016_j_ijcrp_2022_200155 crossref_primary_10_1111_echo_14229 crossref_primary_10_1016_j_jacep_2022_09_012 crossref_primary_10_1536_ihj_19_329 crossref_primary_10_1007_s12272_020_01297_0 crossref_primary_10_1016_j_jacc_2020_05_062 crossref_primary_10_2174_011573403X299868240904120621 crossref_primary_10_1097_MD_0000000000006806 crossref_primary_10_1186_s42444_024_00110_z crossref_primary_10_1016_j_ijcard_2018_11_096 crossref_primary_10_1016_j_hjc_2017_11_006 crossref_primary_10_1536_ihj_20_560 crossref_primary_10_1536_ihj_21_249 crossref_primary_10_1002_joa3_12483 crossref_primary_10_1093_europace_euw088 crossref_primary_10_3389_fonc_2023_1031128 crossref_primary_10_1016_j_ccl_2020_09_013 crossref_primary_10_1253_circj_CJ_15_1250 crossref_primary_10_1016_j_ijcard_2018_10_020 crossref_primary_10_2174_0115748871325292240904060109 crossref_primary_10_1080_00365513_2017_1292364 crossref_primary_10_1002_joa3_12125 crossref_primary_10_1016_j_phrs_2022_106335 crossref_primary_10_1093_europace_euaa009 crossref_primary_10_1016_j_csbj_2020_11_005 crossref_primary_10_1186_s12872_020_01670_3 crossref_primary_10_1161_JAHA_115_002997 crossref_primary_10_1016_j_rec_2024_12_008 crossref_primary_10_1093_ehjci_jeab088 crossref_primary_10_3390_jcm13051307 crossref_primary_10_1016_j_tcm_2015_08_006 crossref_primary_10_3390_ijms22136941 crossref_primary_10_3390_biomedicines9070728 crossref_primary_10_1016_j_ahj_2019_10_009 crossref_primary_10_1007_s10840_024_01946_0 crossref_primary_10_1016_j_cjca_2019_07_008 crossref_primary_10_3389_fnagi_2022_969352 crossref_primary_10_1253_circj_CJ_17_1058 crossref_primary_10_1093_cvr_cvab138 crossref_primary_10_3389_fcvm_2024_1322045 crossref_primary_10_1007_s42399_022_01196_z crossref_primary_10_1016_j_recesp_2024_12_004 crossref_primary_10_1186_s12969_016_0122_4 crossref_primary_10_3389_fcvm_2020_00062 crossref_primary_10_1038_s41374_021_00635_0 crossref_primary_10_1111_jpn_13966 crossref_primary_10_1186_s12872_021_01915_9 crossref_primary_10_3389_fcvm_2020_00114 crossref_primary_10_1016_j_hrthm_2018_10_018 crossref_primary_10_1093_cvr_cvae036 crossref_primary_10_3390_ijms21093226 crossref_primary_10_1159_000540708 crossref_primary_10_3390_ijms24065307 crossref_primary_10_1016_j_jjcc_2023_02_003 crossref_primary_10_7759_cureus_19159 crossref_primary_10_1111_jre_13192 crossref_primary_10_3389_fcell_2022_859421 crossref_primary_10_1111_anec_12833 crossref_primary_10_3389_fphys_2021_793171 crossref_primary_10_3390_jcdd8030024 crossref_primary_10_1039_D3LC00834G crossref_primary_10_1002_jcla_24217 crossref_primary_10_20996_1819_6446_2020_02_15 crossref_primary_10_1161_CIRCEP_115_003721 crossref_primary_10_1007_s00392_020_01619_8 crossref_primary_10_12998_wjcc_v8_i21_5250 crossref_primary_10_1016_j_ahj_2019_09_011 crossref_primary_10_1161_JAHA_121_023152 crossref_primary_10_1002_joa3_12254 crossref_primary_10_1097_PSY_0000000000000854 crossref_primary_10_1016_j_clinre_2017_08_001 crossref_primary_10_3390_life13061260 crossref_primary_10_1111_jce_14898 crossref_primary_10_1016_j_numecd_2021_03_004 crossref_primary_10_1096_fj_202201965RR crossref_primary_10_3390_ijms25010535 crossref_primary_10_3390_nu14091878 crossref_primary_10_4103_jiae_jiae_32_20 crossref_primary_10_1097_01_JAA_0000769672_18363_3f crossref_primary_10_1016_j_hlc_2019_11_004 crossref_primary_10_3389_fendo_2023_1160532 crossref_primary_10_1001_jamacardio_2018_1901 crossref_primary_10_5761_atcs_oa_19_00314 crossref_primary_10_1007_s10787_019_00653_x crossref_primary_10_1055_s_0040_1714400 crossref_primary_10_3389_fcvm_2020_00011 crossref_primary_10_1253_circj_CJ_20_0974 crossref_primary_10_3389_fphys_2018_01482 crossref_primary_10_3389_fnagi_2021_706815 crossref_primary_10_1016_j_numecd_2017_05_009 crossref_primary_10_24207_jca_v32n4_111_IN crossref_primary_10_3233_JAD_200296 crossref_primary_10_1080_17435390_2020_1813824 crossref_primary_10_3389_fphys_2022_739753 crossref_primary_10_1186_s12872_023_03573_5 crossref_primary_10_1007_s13760_020_01335_0 crossref_primary_10_1007_s00380_021_01891_2 crossref_primary_10_4103_0366_6999_157649 crossref_primary_10_1016_j_bcp_2023_115599 crossref_primary_10_1111_pedi_13141 crossref_primary_10_1177_0267659116679248 crossref_primary_10_12659_MSM_895441 crossref_primary_10_1371_journal_pone_0149910 crossref_primary_10_3389_fcvm_2022_879984 crossref_primary_10_3389_fgene_2019_00908 crossref_primary_10_1038_s41371_020_0383_8 crossref_primary_10_3390_jcm12216866 crossref_primary_10_1038_s41569_024_01038_6 crossref_primary_10_1186_s12872_024_04034_3 crossref_primary_10_21886_2712_8156_2021_2_4_22_29 crossref_primary_10_1016_j_bbadis_2021_166170 crossref_primary_10_1080_14779072_2023_2272652 crossref_primary_10_18632_aging_202906 crossref_primary_10_36660_abc_20220295 crossref_primary_10_1152_physrev_00024_2019 crossref_primary_10_1016_j_repce_2020_07_009 crossref_primary_10_3390_diagnostics11020362 crossref_primary_10_1016_j_hlc_2018_06_1056 crossref_primary_10_1186_s12947_020_00205_2 crossref_primary_10_3748_wjg_v25_i22_2788 crossref_primary_10_1016_j_ijcha_2024_101456 crossref_primary_10_3390_antiox13111388 crossref_primary_10_3389_fncel_2023_1073538 crossref_primary_10_3389_fphys_2018_01115 crossref_primary_10_1080_2090598X_2019_1601001 crossref_primary_10_24884_2072_6716_2023_24_1_4_12 crossref_primary_10_1631_jzus_B1600529 crossref_primary_10_3389_fpsyt_2025_1467876 crossref_primary_10_3390_ijms25021082 crossref_primary_10_1002_ehf2_12620 crossref_primary_10_1002_clc_23764 crossref_primary_10_1016_j_ijcard_2016_12_029 crossref_primary_10_1096_fj_201802455RRR |
| Cites_doi | 10.1016/j.ahj.2007.09.006 10.1016/j.hrthm.2009.10.004 10.1016/j.ijcard.2008.12.052 10.1016/j.thromres.2011.07.013 10.1371/journal.pone.0099495 10.1016/S0140-6736(09)60040-4 10.1016/j.cjca.2013.12.010 10.1007/s00395-013-0356-y 10.1080/14017430802651803 10.1161/CIRCULATIONAHA.107.704759 10.1016/j.ijcard.2008.04.087 10.1093/eurheartj/ehr460 10.1136/heartjnl-2011-300245 10.1016/j.ijcard.2005.05.021 10.1161/01.ATV.17.12.3399 10.1093/europace/eut312 10.3109/07853890.2010.546362 10.1093/europace/eur208 10.1016/j.cjca.2012.05.003 10.1093/europace/eun111 10.1111/j.1540-8167.2010.01919.x 10.1161/hc4901.101760 10.1016/j.jacc.2013.02.045 10.1016/j.ahj.2004.01.026 10.1016/j.cjca.2012.06.009 10.1111/j.1540-8167.2011.02059.x 10.1016/j.ijcard.2012.08.056 10.1161/CIRCRESAHA.114.303211 10.1161/CIRCULATIONAHA.108.848218 10.1016/j.accreview.2004.07.087 10.1016/j.cardiores.2005.11.028 10.1016/j.hrthm.2014.07.030 10.1161/01.CIR.96.4.1180 10.1161/CIRCRESAHA.114.302699 10.1161/01.CIR.0000145163.56529.D1 10.1097/FJC.0b013e31817f9398 10.1016/j.jacc.2012.11.046 10.1038/nm.2124 10.1161/CIRCRESAHA.110.226928 10.1253/circj.CJ-11-0795 10.1001/jama.2014.11026 10.1253/circj.CJ-12-1155 10.1253/circj.CJ-09-0644 10.1253/circj.CJ-12-0728 10.1016/j.jacc.2010.04.057 10.1161/hh1801.097644 10.1371/journal.pone.0065817 10.1111/ijcp.12304 10.1016/j.jacc.2014.02.555 10.1016/j.ijcard.2008.04.012 10.1016/j.hrthm.2011.09.016 10.1016/j.jacc.2012.04.063 10.1136/bmj.d1250 10.1161/CIRCULATIONAHA.111.026153 10.1016/j.yjmcc.2013.04.019 10.1042/CS20080372 10.1161/CIRCULATIONAHA.114.011204 10.1016/j.jacc.2013.07.014 10.1016/j.hrthm.2009.12.009 10.1016/j.amjcard.2004.06.011 10.12659/MSM.890635 10.1161/01.STR.31.10.2287 10.1161/STROKEAHA.110.586289 10.1016/j.jacc.2010.02.066 10.1016/j.ijcard.2013.08.078 10.1111/j.1538-7836.2012.04812.x 10.1016/j.jacc.2014.07.956 10.1172/JCI39942 10.1016/j.amjcard.2008.05.038 10.1111/eci.12237 10.1016/j.hrthm.2006.11.026 10.1182/blood.V82.2.513.513 10.1016/j.amjcard.2011.08.010 10.1016/j.jacc.2007.09.064 10.1016/j.ijcard.2004.12.041 10.1161/01.STR.0000051728.85133.32 10.1152/ajpcell.00186.2007 |
| ContentType | Journal Article |
| Copyright | 2015 THE JAPANESE CIRCULATION SOCIETY |
| Copyright_xml | – notice: 2015 THE JAPANESE CIRCULATION SOCIETY |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1253/circj.CJ-15-0138 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1347-4820 |
| EndPage | 502 |
| ExternalDocumentID | PMC4457364 25746525 10_1253_circj_CJ_15_0138 article_circj_79_3_79_CJ_15_0138_article_char_en |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Canadian Institutes of Health Research grantid: 6957 – fundername: NHLBI NIH HHS grantid: R01 HL111314 – fundername: Canadian Institutes of Health Research grantid: 44365 – fundername: NHLBI NIH HHS grantid: 1R01HL111314 |
| GroupedDBID | --- .55 29B 2WC 53G 5GY 5RE 6J9 ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 OK1 OVT P2P RJT RNS RZJ TR2 W2D X7M XSB ZXP .GJ 3O- AAYXX CITATION TKC CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c677t-6cdd66f221d1f6e19b9ce158db47913dc22d40a9566df823f838f15f175bfbbf3 |
| ISSN | 1346-9843 1347-4820 |
| IngestDate | Thu Aug 21 18:34:26 EDT 2025 Fri Jul 11 15:57:58 EDT 2025 Thu Apr 03 07:09:07 EDT 2025 Tue Jul 01 02:01:14 EDT 2025 Thu Apr 24 23:00:50 EDT 2025 Wed Sep 03 06:15:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c677t-6cdd66f221d1f6e19b9ce158db47913dc22d40a9566df823f838f15f175bfbbf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/circj/79/3/79_CJ-15-0138/_article/-char/en |
| PMID | 25746525 |
| PQID | 1661995947 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4457364 proquest_miscellaneous_1661995947 pubmed_primary_25746525 crossref_citationtrail_10_1253_circj_CJ_15_0138 crossref_primary_10_1253_circj_CJ_15_0138 jstage_primary_article_circj_79_3_79_CJ_15_0138_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-00-00 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – year: 2015 text: 2015-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Circulation Journal |
| PublicationTitleAlternate | Circ J |
| PublicationYear | 2015 |
| Publisher | The Japanese Circulation Society |
| Publisher_xml | – name: The Japanese Circulation Society |
| References | 26. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk?: A Mendelian randomization of 47000 individuals from the general population. J Am Coll Cardiol 2010; 56: 789–795. 44. Ito K, Date T, Ikegami M, Hongo K, Fujisaki M, Katoh D, et al. An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS One 2013; 8: e65817, doi:10.1371/journal.pone.0065817. 24. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, et al. NF-κB-dependent transcriptional regulation of the cardiac SCN5a sodium channel by angiotensin. Am J Physiol Cell Physiol 2008; 294: C372–C379. 41. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292–297. 43. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011; 22: 987–993. 47. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531–537. 7. Duchatelle V, Kritikou EA, Tardif JC. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Can J Cardiol 2012; 28: 678–686. 35. Pinto A, Tuttolomondo A, Casuccio A, Raimondo DD, Sciacca RD, Arnao V, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation. Clin Sci 2009; 116: 781–789. 42. Sonmez O, Ertem FU, Vatankulu MA, Erdogan E, Tasal A, Kucukbuzcu S, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit 2014; 20: 463–470. 5. Hofmann U, Frantz S. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol 2013; 108: 356. 64. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011; 124: 2290–2295. 60. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005; 102: 321–326. 4. Maesen B, Maessen JN, Allessie M, Schotten U. Post-operative atrial fibrillation: A maze of mechanisms. Europace 2012; 14: 159–174. 46. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation-promotion by atrial tachycardia remodeling in dogs. Circulation 2004; 110: 2313–2319. 12. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JRB, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. PLoS One 2014; 9: e99495, doi:10.1371/journal.pone.0099495. 39. Izumiya Y, Hanatani S, Kimura Y, Yamamoto E, Kusaka H, Tokitsu T, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338–344. 40. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802–809. 65. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: The COPPS-2 randomized clinical trial. JAMA 2014; 312: 1016–1023. 74. Lim HS, Willoughby SR, Schultz C, Chakrabarty A, Alasady M, Lau DH, et al. Successful catheter ablation decreases platelet activation and improves endothelial function in patients with atrial fibrillation. Heart Rhythm 2014; 11: 1912–1918. 29. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 148: 462–466. 31. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462–466. 48. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al. Effect of statins on atrial fibrillation: Collaborative meta-analysis of published and unpublished evidence from randomized controlled trials. BMJ 2011; 342: d11250. 6. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867–1879. 16. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470–474. 2. Vilchez JA, Roldan V, Hernandez-Romero D, Valdes M, Lip GY, Marin F. Biomarkers in atrial fibrillation: An overview. Int J Clin Pract 2014; 68: 434–443. 73. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: Involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128: e113–e118, doi:10.1016/j.thromres.2011.07.013. 18. Liao C, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120: 242–253. 66. Thambidorai SK, Parakh K, Martin DO. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805–807. 49. Bang CN, Greve AM, Abdulla J, Kober L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol 2013; 167: 624–630. 21. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: To be or not to be NF-κB. Circ Res 2011; 108: 1122–1132. 68. Shin SY, Na JO, Lim HE, Choi CU, Choi JI, Kim SH, et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol 2011; 22: 376–382. 50. Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: A double-blind, placebo-controlled, randomized trial. Heart Rhythm 2012; 9: 172–178. 30. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation. Am J Cardiol 2012; 109: 95–99. 34. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. The role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438–444. 17. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262–270. 55. Won H, Kim JY, Shim J, Uhm JS, Pak HN, Lee MH, et al. Effect of a single bolus injection of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after radiofrequency catheter ablation. Circ J 2013; 77: 53–59. 57. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89: E32–E38. 75. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–520. 51. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006; 69: 865–875. 8. Schiffrin EL. The immune system: Role in hypertension. Can J Cardiol 2013; 29: 543–548. 70. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: The Rotterdam study. Stroke 2010; 41: 2151–2156. 10. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: Role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52: 306–313. 69. Tousoulis D, Zisimos K, Antoniades C, Stefanadi E, Siasos G, Tsioufis C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distention. Int J Cardiol 2009; 136: 258–262. 54. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamazaki H, Kuroki K, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation. J Am Col Cardiol 2010; 56: 1463–1472. 56. Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community: The Shibata study. Stroke 2000; 31: 2287–2294. 77. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331–340. 37. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, et al. The predictive value of inflammatory and oxydative markers following the successful cardioversion of persistent lone atrial f 44 45 46 47 48 49 50 51 52 53 10 54 11 55 12 56 13 57 14 58 15 59 16 17 18 19 1 2 3 4 5 6 7 8 9 60 61 62 63 20 64 21 65 22 66 23 67 24 68 25 69 26 27 28 29 70 71 72 73 30 74 31 75 32 76 33 77 34 35 36 37 38 39 40 41 42 43 17967774 - Circulation. 2007 Nov 6;116(19):2101-9 22926034 - Can J Cardiol. 2012 Nov-Dec;28(6):678-86 23643589 - J Mol Cell Cardiol. 2013 Sep;62:72-9 24484911 - Can J Cardiol. 2014 Mar;30(3):338-44 9286947 - Circulation. 1997 Aug 19;96(4):1180-4 24763464 - Circ Res. 2014 Apr 25;114(9):1453-68 8329706 - Blood. 1993 Jul 15;82(2):513-20 25068571 - Heart Rhythm. 2014 Nov;11(11):1912-8 24902971 - Circ Res. 2014 Jun 6;114(12):1867-79 21962993 - Am J Cardiol. 2012 Jan 1;109(1):95-9 18791466 - J Cardiovasc Pharmacol. 2008 Oct;52(4):306-13 20798373 - Stroke. 2010 Oct;41(10):2151-6 20009387 - Circ J. 2010 Feb;74(2):262-70 20153266 - Heart Rhythm. 2010 Apr;7(4):438-44 23194937 - J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70 18640731 - Int J Cardiol. 2009 Jul 10;135(3):361-9 11022052 - Stroke. 2000 Oct;31(10):2287-94 23740214 - Basic Res Cardiol. 2013 Jul;108(4):356 24372915 - Int J Clin Pract. 2014 Apr;68(4):434-43 21824645 - Thromb Res. 2011 Dec;128(6):e113-8 23785453 - PLoS One. 2013;8(6):e65817 11557745 - Circ Res. 2001 Sep 14;89(6):E32-8 16405878 - Cardiovasc Res. 2006 Mar 1;69(4):865-75 9437185 - Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3399-405 20022819 - Heart Rhythm. 2010;7(2):149-54 15982504 - Int J Cardiol. 2005 Jul 10;102(2):321-6 21821851 - Europace. 2012 Feb;14(2):159-74 19169931 - Scand Cardiovasc J. 2009;43(5):292-7 17399635 - Heart Rhythm. 2007 Apr;4(4):461-8 19332460 - Circulation. 2009 Apr 14;119(14):1853-66 24095158 - Int J Cardiol. 2013 Oct 25;169(1):62-72 21411487 - BMJ. 2011;342:d1250 22681487 - J Thromb Haemost. 2012 Aug;10(8):1500-7 21244217 - Ann Med. 2011 Aug;43(5):331-40 18980576 - Clin Sci (Lond). 2009 May;116(10):781-9 15389233 - Am Heart J. 2004 Sep;148(3):462-6 25277614 - J Am Coll Cardiol. 2014 Oct 7;64(14):1441-8 22090167 - Circulation. 2011 Nov 22;124(21):2290-5 15374796 - Am J Cardiol. 2004 Sep 15;94(6):805-7 21489023 - J Cardiovasc Electrophysiol. 2011 Sep;22(9):987-93 23916928 - J Am Coll Cardiol. 2013 Oct 15;62(16):1457-65 25172965 - JAMA. 2014 Sep 10;312(10):1016-23 11739301 - Circulation. 2001 Dec 11;104(24):2886-91 22001292 - Circ J. 2011;75(12):2781-8 18294563 - J Am Coll Cardiol. 2008 Feb 26;51(8):802-9 24923671 - PLoS One. 2014;9(6):e99495 19178964 - Int J Cardiol. 2010 Jun 25;142(1):22-8 21527742 - Circ Res. 2011 Apr 29;108(9):1122-32 18657327 - Int J Cardiol. 2009 Aug 21;136(3):258-62 18032528 - Am J Physiol Cell Physiol. 2008 Jan;294(1):C372-9 18805111 - Am J Cardiol. 2008 Oct 1;102(7):861-5 24108228 - Europace. 2014 Apr;16(4):477-84 20038802 - J Clin Invest. 2010 Jan;120(1):242-53 23333141 - J Am Coll Cardiol. 2013 Feb 26;61(8):852-60 23541970 - J Am Coll Cardiol. 2013 May 28;61(21):2194-6 24651058 - Med Sci Monit. 2014;20:463-70 15172416 - J Am Coll Cardiol. 2004 Jun 2;43(11):2075-82 18215601 - Am Heart J. 2008 Feb;155(2):303-9 15477401 - Circulation. 2004 Oct 19;110(16):2313-9 20958832 - J Cardiovasc Electrophysiol. 2011 Apr;22(4):376-82 21865202 - Heart. 2011 Oct;97(20):1636-42 23006726 - Circ J. 2013;77(1):53-9 20797493 - J Am Coll Cardiol. 2010 Aug 31;56(10):789-95 20951321 - J Am Coll Cardiol. 2010 Oct 26;56(18):1463-72 22902155 - Can J Cardiol. 2013 May;29(5):543-8 19135613 - Lancet. 2009 Jan 10;373(9658):155-66 25294786 - Circulation. 2014 Nov 18;130(21):1847-58 12574552 - Stroke. 2003 Feb;34(2):413-7 20305660 - Nat Med. 2010 Apr;16(4):470-4 23370453 - Circ J. 2013;77(5):1171-9 24387767 - Eur J Clin Invest. 2014 Apr;44(4):402-28 22187510 - Eur Heart J. 2012 Feb;33(4):531-7 18523031 - Europace. 2008 Jul;10(7):848-53 22999824 - Int J Cardiol. 2013 Aug 10;167(3):624-30 24613319 - J Am Coll Cardiol. 2014 Jun 10;63(22):2335-45 21920481 - Heart Rhythm. 2012 Feb;9(2):172-8 15964643 - Int J Cardiol. 2006 Apr 14;108(3):346-53 |
| References_xml | – reference: 33. Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhawar N, et al. Intra and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010; 7: 149–154. – reference: 17. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262–270. – reference: 24. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, et al. NF-κB-dependent transcriptional regulation of the cardiac SCN5a sodium channel by angiotensin. Am J Physiol Cell Physiol 2008; 294: C372–C379. – reference: 57. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89: E32–E38. – reference: 15. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol 2008; 102: 861–865. – reference: 22. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J 2013; 77: 1171–1179. – reference: 1. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Col Cardiol 2012; 60: 2263–2270. – reference: 46. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation-promotion by atrial tachycardia remodeling in dogs. Circulation 2004; 110: 2313–2319. – reference: 32. Roldan V, Marin F, Diaz J, Gallego P, Jover E, Romera M, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012; 10: 1500–1507. – reference: 65. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: The COPPS-2 randomized clinical trial. JAMA 2014; 312: 1016–1023. – reference: 35. Pinto A, Tuttolomondo A, Casuccio A, Raimondo DD, Sciacca RD, Arnao V, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation. Clin Sci 2009; 116: 781–789. – reference: 8. Schiffrin EL. The immune system: Role in hypertension. Can J Cardiol 2013; 29: 543–548. – reference: 20. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Mechanisms and implications. J Am Coll Cardiol 2014; 63: 2335–2345. – reference: 27. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitive C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346–353. – reference: 25. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Cames CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886–2891. – reference: 11. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155–166. – reference: 75. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–520. – reference: 64. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011; 124: 2290–2295. – reference: 47. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531–537. – reference: 71. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: The Rotterdam Study. Stroke 2003; 34: 413–417. – reference: 13. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study. Am Heart J 2008; 155: 303–309. – reference: 53. Baker WL, White CM, Kluger J, Denowitz A, Konecny CP, Coleman Cl. Effect of perioperative corticosteroids use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm 2007; 4: 461–468. – reference: 73. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: Involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128: e113–e118, doi:10.1016/j.thromres.2011.07.013. – reference: 3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180–1184. – reference: 21. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: To be or not to be NF-κB. Circ Res 2011; 108: 1122–1132. – reference: 49. Bang CN, Greve AM, Abdulla J, Kober L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol 2013; 167: 624–630. – reference: 38. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 130: 1847–1858. – reference: 18. Liao C, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120: 242–253. – reference: 50. Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: A double-blind, placebo-controlled, randomized trial. Heart Rhythm 2012; 9: 172–178. – reference: 52. Ho KM, Tan JA. Benefits and risk of corticosteroid prophylaxis in adult cardiac surgery: A dose-response meta-analysis. Circulation 2009; 119: 1853–1866. – reference: 19. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, et al. Oxidative stress in atrial fibrillation: An emerging role of NADPH oxidase. J Mol Cell Cardiol 2013; 62: 72–79. – reference: 63. Mozaffarian D, Wu JH, de Oliveira Otto MC, Sandesara CM, Metcalf RG, Latini R, et al. Fish oil and post-operative atrial fibrillation: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2013; 61: 2194–2196. – reference: 28. Wu N, Xiang Y, Wu L, Zhang Y, Ma X, Tong S, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol 2013; 169: 62–72. – reference: 45. Jacob KA, Nathoe HM, Deleman JM, Osch DV, Kluin J, Dijik DV. Inflammation in new-onset atrial fibrillation after cardiac surgery: A systematic review. Eur J Clin Invest 2014; 44: 402–428. – reference: 74. Lim HS, Willoughby SR, Schultz C, Chakrabarty A, Alasady M, Lau DH, et al. Successful catheter ablation decreases platelet activation and improves endothelial function in patients with atrial fibrillation. Heart Rhythm 2014; 11: 1912–1918. – reference: 58. Harling L, Rasoli S, Vecht JA, Ashrafian H, Kourliouros A, Athanasiou T. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97: 1636–1642. – reference: 2. Vilchez JA, Roldan V, Hernandez-Romero D, Valdes M, Lip GY, Marin F. Biomarkers in atrial fibrillation: An overview. Int J Clin Pract 2014; 68: 434–443. – reference: 9. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation relationship among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453–1468. – reference: 34. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. The role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438–444. – reference: 55. Won H, Kim JY, Shim J, Uhm JS, Pak HN, Lee MH, et al. Effect of a single bolus injection of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after radiofrequency catheter ablation. Circ J 2013; 77: 53–59. – reference: 54. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamazaki H, Kuroki K, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation. J Am Col Cardiol 2010; 56: 1463–1472. – reference: 66. Thambidorai SK, Parakh K, Martin DO. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805–807. – reference: 44. Ito K, Date T, Ikegami M, Hongo K, Fujisaki M, Katoh D, et al. An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS One 2013; 8: e65817, doi:10.1371/journal.pone.0065817. – reference: 39. Izumiya Y, Hanatani S, Kimura Y, Yamamoto E, Kusaka H, Tokitsu T, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338–344. – reference: 72. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: Impact of rate and rhythm. J Am Coll Cardiol 2013; 61: 852–860. – reference: 77. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331–340. – reference: 30. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation. Am J Cardiol 2012; 109: 95–99. – reference: 41. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292–297. – reference: 70. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: The Rotterdam study. Stroke 2010; 41: 2151–2156. – reference: 59. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62: 1457–1465. – reference: 12. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JRB, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. PLoS One 2014; 9: e99495, doi:10.1371/journal.pone.0099495. – reference: 48. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al. Effect of statins on atrial fibrillation: Collaborative meta-analysis of published and unpublished evidence from randomized controlled trials. BMJ 2011; 342: d11250. – reference: 42. Sonmez O, Ertem FU, Vatankulu MA, Erdogan E, Tasal A, Kucukbuzcu S, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit 2014; 20: 463–470. – reference: 29. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 148: 462–466. – reference: 23. Cao H, Wang J, Xi L, Roe OD, Chen Y, Wang D. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. Circ J 2011; 75: 2781–2788. – reference: 61. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116: 2101–2109. – reference: 14. Kristensen SL, Lindhardsen J, Ahlehoff O, Lamberts M, Khalid U, Torp-pedersen C, et al. Increased risk of atrial fibrillation and stroke during active stage of inflammatory bowel disease: A nationwide study. Europace 2014; 16: 477–484. – reference: 16. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470–474. – reference: 56. Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community: The Shibata study. Stroke 2000; 31: 2287–2294. – reference: 69. Tousoulis D, Zisimos K, Antoniades C, Stefanadi E, Siasos G, Tsioufis C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distention. Int J Cardiol 2009; 136: 258–262. – reference: 76. Neumann FJ, Ott I, Matx N, Luther T, Gawaz M, Kotzsch M, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17: 3399–3405. – reference: 60. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005; 102: 321–326. – reference: 43. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011; 22: 987–993. – reference: 7. Duchatelle V, Kritikou EA, Tardif JC. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Can J Cardiol 2012; 28: 678–686. – reference: 26. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk?: A Mendelian randomization of 47000 individuals from the general population. J Am Coll Cardiol 2010; 56: 789–795. – reference: 37. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, et al. The predictive value of inflammatory and oxydative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135: 361–369. – reference: 62. Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al; AFFORD Investigators. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J Am Coll Cardiol 2014; 64: 1441–1448. – reference: 67. Cianfrocca C, Loricchio ML, Pelliccia F, Pasceri V, Auriti A, Bianconi L, et al. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation. Int J Cardiol 2010; 142: 22–28. – reference: 4. Maesen B, Maessen JN, Allessie M, Schotten U. Post-operative atrial fibrillation: A maze of mechanisms. Europace 2012; 14: 159–174. – reference: 10. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: Role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52: 306–313. – reference: 51. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006; 69: 865–875. – reference: 6. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867–1879. – reference: 36. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008; 10: 848–853. – reference: 68. Shin SY, Na JO, Lim HE, Choi CU, Choi JI, Kim SH, et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol 2011; 22: 376–382. – reference: 5. Hofmann U, Frantz S. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol 2013; 108: 356. – reference: 31. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462–466. – reference: 40. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802–809. – ident: 13 doi: 10.1016/j.ahj.2007.09.006 – ident: 33 doi: 10.1016/j.hrthm.2009.10.004 – ident: 67 doi: 10.1016/j.ijcard.2008.12.052 – ident: 73 doi: 10.1016/j.thromres.2011.07.013 – ident: 12 doi: 10.1371/journal.pone.0099495 – ident: 11 doi: 10.1016/S0140-6736(09)60040-4 – ident: 39 doi: 10.1016/j.cjca.2013.12.010 – ident: 5 doi: 10.1007/s00395-013-0356-y – ident: 41 doi: 10.1080/14017430802651803 – ident: 61 doi: 10.1161/CIRCULATIONAHA.107.704759 – ident: 69 doi: 10.1016/j.ijcard.2008.04.087 – ident: 47 doi: 10.1093/eurheartj/ehr460 – ident: 58 doi: 10.1136/heartjnl-2011-300245 – ident: 27 doi: 10.1016/j.ijcard.2005.05.021 – ident: 76 doi: 10.1161/01.ATV.17.12.3399 – ident: 14 doi: 10.1093/europace/eut312 – ident: 77 doi: 10.3109/07853890.2010.546362 – ident: 4 doi: 10.1093/europace/eur208 – ident: 7 doi: 10.1016/j.cjca.2012.05.003 – ident: 36 doi: 10.1093/europace/eun111 – ident: 68 doi: 10.1111/j.1540-8167.2010.01919.x – ident: 25 doi: 10.1161/hc4901.101760 – ident: 63 doi: 10.1016/j.jacc.2013.02.045 – ident: 31 doi: 10.1016/j.ahj.2004.01.026 – ident: 8 doi: 10.1016/j.cjca.2012.06.009 – ident: 43 doi: 10.1111/j.1540-8167.2011.02059.x – ident: 49 doi: 10.1016/j.ijcard.2012.08.056 – ident: 9 doi: 10.1161/CIRCRESAHA.114.303211 – ident: 52 doi: 10.1161/CIRCULATIONAHA.108.848218 – ident: 29 doi: 10.1016/j.accreview.2004.07.087 – ident: 51 doi: 10.1016/j.cardiores.2005.11.028 – ident: 74 doi: 10.1016/j.hrthm.2014.07.030 – ident: 3 doi: 10.1161/01.CIR.96.4.1180 – ident: 6 doi: 10.1161/CIRCRESAHA.114.302699 – ident: 46 doi: 10.1161/01.CIR.0000145163.56529.D1 – ident: 10 doi: 10.1097/FJC.0b013e31817f9398 – ident: 72 doi: 10.1016/j.jacc.2012.11.046 – ident: 16 doi: 10.1038/nm.2124 – ident: 21 doi: 10.1161/CIRCRESAHA.110.226928 – ident: 23 doi: 10.1253/circj.CJ-11-0795 – ident: 65 doi: 10.1001/jama.2014.11026 – ident: 22 doi: 10.1253/circj.CJ-12-1155 – ident: 17 doi: 10.1253/circj.CJ-09-0644 – ident: 55 doi: 10.1253/circj.CJ-12-0728 – ident: 54 doi: 10.1016/j.jacc.2010.04.057 – ident: 57 doi: 10.1161/hh1801.097644 – ident: 44 doi: 10.1371/journal.pone.0065817 – ident: 2 doi: 10.1111/ijcp.12304 – ident: 20 doi: 10.1016/j.jacc.2014.02.555 – ident: 37 doi: 10.1016/j.ijcard.2008.04.012 – ident: 50 doi: 10.1016/j.hrthm.2011.09.016 – ident: 1 doi: 10.1016/j.jacc.2012.04.063 – ident: 48 doi: 10.1136/bmj.d1250 – ident: 64 doi: 10.1161/CIRCULATIONAHA.111.026153 – ident: 19 doi: 10.1016/j.yjmcc.2013.04.019 – ident: 35 doi: 10.1042/CS20080372 – ident: 38 doi: 10.1161/CIRCULATIONAHA.114.011204 – ident: 59 doi: 10.1016/j.jacc.2013.07.014 – ident: 34 doi: 10.1016/j.hrthm.2009.12.009 – ident: 66 doi: 10.1016/j.amjcard.2004.06.011 – ident: 42 doi: 10.12659/MSM.890635 – ident: 56 doi: 10.1161/01.STR.31.10.2287 – ident: 70 doi: 10.1161/STROKEAHA.110.586289 – ident: 26 doi: 10.1016/j.jacc.2010.02.066 – ident: 28 doi: 10.1016/j.ijcard.2013.08.078 – ident: 32 doi: 10.1111/j.1538-7836.2012.04812.x – ident: 62 doi: 10.1016/j.jacc.2014.07.956 – ident: 18 doi: 10.1172/JCI39942 – ident: 15 doi: 10.1016/j.amjcard.2008.05.038 – ident: 45 doi: 10.1111/eci.12237 – ident: 53 doi: 10.1016/j.hrthm.2006.11.026 – ident: 75 doi: 10.1182/blood.V82.2.513.513 – ident: 30 doi: 10.1016/j.amjcard.2011.08.010 – ident: 40 doi: 10.1016/j.jacc.2007.09.064 – ident: 60 doi: 10.1016/j.ijcard.2004.12.041 – ident: 71 doi: 10.1161/01.STR.0000051728.85133.32 – ident: 24 doi: 10.1152/ajpcell.00186.2007 – reference: 22187510 - Eur Heart J. 2012 Feb;33(4):531-7 – reference: 17399635 - Heart Rhythm. 2007 Apr;4(4):461-8 – reference: 24902971 - Circ Res. 2014 Jun 6;114(12):1867-79 – reference: 21527742 - Circ Res. 2011 Apr 29;108(9):1122-32 – reference: 25294786 - Circulation. 2014 Nov 18;130(21):1847-58 – reference: 9437185 - Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3399-405 – reference: 18032528 - Am J Physiol Cell Physiol. 2008 Jan;294(1):C372-9 – reference: 25277614 - J Am Coll Cardiol. 2014 Oct 7;64(14):1441-8 – reference: 11022052 - Stroke. 2000 Oct;31(10):2287-94 – reference: 20951321 - J Am Coll Cardiol. 2010 Oct 26;56(18):1463-72 – reference: 20958832 - J Cardiovasc Electrophysiol. 2011 Apr;22(4):376-82 – reference: 15389233 - Am Heart J. 2004 Sep;148(3):462-6 – reference: 22681487 - J Thromb Haemost. 2012 Aug;10(8):1500-7 – reference: 15964643 - Int J Cardiol. 2006 Apr 14;108(3):346-53 – reference: 11557745 - Circ Res. 2001 Sep 14;89(6):E32-8 – reference: 15982504 - Int J Cardiol. 2005 Jul 10;102(2):321-6 – reference: 18791466 - J Cardiovasc Pharmacol. 2008 Oct;52(4):306-13 – reference: 23643589 - J Mol Cell Cardiol. 2013 Sep;62:72-9 – reference: 18805111 - Am J Cardiol. 2008 Oct 1;102(7):861-5 – reference: 20153266 - Heart Rhythm. 2010 Apr;7(4):438-44 – reference: 22001292 - Circ J. 2011;75(12):2781-8 – reference: 21244217 - Ann Med. 2011 Aug;43(5):331-40 – reference: 20797493 - J Am Coll Cardiol. 2010 Aug 31;56(10):789-95 – reference: 24484911 - Can J Cardiol. 2014 Mar;30(3):338-44 – reference: 20009387 - Circ J. 2010 Feb;74(2):262-70 – reference: 23541970 - J Am Coll Cardiol. 2013 May 28;61(21):2194-6 – reference: 18523031 - Europace. 2008 Jul;10(7):848-53 – reference: 16405878 - Cardiovasc Res. 2006 Mar 1;69(4):865-75 – reference: 24387767 - Eur J Clin Invest. 2014 Apr;44(4):402-28 – reference: 19178964 - Int J Cardiol. 2010 Jun 25;142(1):22-8 – reference: 20038802 - J Clin Invest. 2010 Jan;120(1):242-53 – reference: 22090167 - Circulation. 2011 Nov 22;124(21):2290-5 – reference: 22926034 - Can J Cardiol. 2012 Nov-Dec;28(6):678-86 – reference: 20798373 - Stroke. 2010 Oct;41(10):2151-6 – reference: 20022819 - Heart Rhythm. 2010;7(2):149-54 – reference: 23916928 - J Am Coll Cardiol. 2013 Oct 15;62(16):1457-65 – reference: 20305660 - Nat Med. 2010 Apr;16(4):470-4 – reference: 23006726 - Circ J. 2013;77(1):53-9 – reference: 21821851 - Europace. 2012 Feb;14(2):159-74 – reference: 22999824 - Int J Cardiol. 2013 Aug 10;167(3):624-30 – reference: 24651058 - Med Sci Monit. 2014;20:463-70 – reference: 25172965 - JAMA. 2014 Sep 10;312(10):1016-23 – reference: 18294563 - J Am Coll Cardiol. 2008 Feb 26;51(8):802-9 – reference: 23333141 - J Am Coll Cardiol. 2013 Feb 26;61(8):852-60 – reference: 25068571 - Heart Rhythm. 2014 Nov;11(11):1912-8 – reference: 21824645 - Thromb Res. 2011 Dec;128(6):e113-8 – reference: 15172416 - J Am Coll Cardiol. 2004 Jun 2;43(11):2075-82 – reference: 24372915 - Int J Clin Pract. 2014 Apr;68(4):434-43 – reference: 23370453 - Circ J. 2013;77(5):1171-9 – reference: 11739301 - Circulation. 2001 Dec 11;104(24):2886-91 – reference: 21962993 - Am J Cardiol. 2012 Jan 1;109(1):95-9 – reference: 18980576 - Clin Sci (Lond). 2009 May;116(10):781-9 – reference: 24923671 - PLoS One. 2014;9(6):e99495 – reference: 22902155 - Can J Cardiol. 2013 May;29(5):543-8 – reference: 21865202 - Heart. 2011 Oct;97(20):1636-42 – reference: 15477401 - Circulation. 2004 Oct 19;110(16):2313-9 – reference: 18657327 - Int J Cardiol. 2009 Aug 21;136(3):258-62 – reference: 19135613 - Lancet. 2009 Jan 10;373(9658):155-66 – reference: 18640731 - Int J Cardiol. 2009 Jul 10;135(3):361-9 – reference: 23785453 - PLoS One. 2013;8(6):e65817 – reference: 12574552 - Stroke. 2003 Feb;34(2):413-7 – reference: 15374796 - Am J Cardiol. 2004 Sep 15;94(6):805-7 – reference: 24763464 - Circ Res. 2014 Apr 25;114(9):1453-68 – reference: 19169931 - Scand Cardiovasc J. 2009;43(5):292-7 – reference: 17967774 - Circulation. 2007 Nov 6;116(19):2101-9 – reference: 23194937 - J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70 – reference: 19332460 - Circulation. 2009 Apr 14;119(14):1853-66 – reference: 21411487 - BMJ. 2011;342:d1250 – reference: 23740214 - Basic Res Cardiol. 2013 Jul;108(4):356 – reference: 21920481 - Heart Rhythm. 2012 Feb;9(2):172-8 – reference: 21489023 - J Cardiovasc Electrophysiol. 2011 Sep;22(9):987-93 – reference: 24095158 - Int J Cardiol. 2013 Oct 25;169(1):62-72 – reference: 9286947 - Circulation. 1997 Aug 19;96(4):1180-4 – reference: 8329706 - Blood. 1993 Jul 15;82(2):513-20 – reference: 24108228 - Europace. 2014 Apr;16(4):477-84 – reference: 24613319 - J Am Coll Cardiol. 2014 Jun 10;63(22):2335-45 – reference: 18215601 - Am Heart J. 2008 Feb;155(2):303-9 |
| SSID | ssj0029059 |
| Score | 2.5672905 |
| SecondaryResourceType | review_article |
| Snippet | Atrial fibrillation (AF) is the most common clinically relevant arrhythmia, but the methods available for treating AF and its complications (of which the most... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 495 |
| SubjectTerms | Animals Anti-inflammatory drugs Apoptosis Atrial fibrillation Atrial Fibrillation - blood Atrial Fibrillation - physiopathology Atrial Fibrillation - therapy Biomarkers Blood Coagulation Fibrosis Humans Inflammation - blood Inflammation - pathology Inflammation - physiopathology Inflammation Mediators - blood Inflammatory markers Oxidative Stress Thrombogenesis |
| Title | Role of Inflammation in Atrial Fibrillation Pathophysiology and Management |
| URI | https://www.jstage.jst.go.jp/article/circj/79/3/79_CJ-15-0138/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/25746525 https://www.proquest.com/docview/1661995947 https://pubmed.ncbi.nlm.nih.gov/PMC4457364 |
| Volume | 79 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Circulation Journal, 2015/02/25, Vol.79(3), pp.495-502 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgIMQL4puMDwWJF4SyxR-JkyeEqo0p2oqEWuibFdvx2qm0U9e98Ndzjt18lIIGL1br-iP1nS_n893vEHqHtTGUMhYZmqqIKS6jTNMkirmKNZVUmdrgdjZMT8asmCST1qBfR5es5YH6uTOu5H-oCnVAVxsl-w-UbQaFCvgM9IUSKAzljWj81bsGwlhAWBeEaA0YpcvFYaw7_9w5u1kA1emytmO0qEs_-r4vG8CC2Ur5pF4NsMSf0Cas2lrA-9bmsfzQ7ei9QVsBtyp16YKDrsrpTDf89A0EzPfyfOkDb2of-9aLcWjhP-fOHa1cbC6hvZXCRWh6kUoZj1hG3O1LtaPOy2GXVMbzG-0IVebScP4m7EmdsUPBf7s4GBQRtl6IDiqmj6s9_CKOx6enYnQ0Gd1GdwgcKKwI_zxpnIFIHtdp9Zrn8hfaMMPh9vg9BebuBejw59Wu48m2l21HbRk9RA_8eSP85JjnEbpVLR6je2feo-IJKiwPhUsTdnkIvoSOh8IuD4VbPBQCD4UtDz1F4-Oj0eAk8vk1IpVyvo5SpXWaGkKwxiatcC5zVeEk05LxHFOtCNEsLuEEnWqTEWoymhmcGNA4pZHS0GdobwHs8QKFEhRpLDFol5wyYnQmDWZJrEoemzJmOECHm0UTyoPP2xwoc2EPobDMol5mMSgEToRd5gC9b3pcOuCVv7T96OjQtPRb0rfkuaC2aHu0DablCkRJgN5uCChAvtpLM9g5y-srgUGBtZh8jAfouSNoMwu87liakCRAvEfqpoHFbu__sphNawx3xhJOU7Z_g3lfovt2Rzm73yu0t15dV69BE17LNzUT_wLksr0B |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+inflammation+in+atrial+fibrillation+pathophysiology+and+management&rft.jtitle=Circulation+journal+%3A+official+journal+of+the+Japanese+Circulation+Society&rft.au=Harada%2C+Masahide&rft.au=Van+Wagoner%2C+David+R&rft.au=Nattel%2C+Stanley&rft.date=2015&rft.issn=1347-4820&rft.eissn=1347-4820&rft.volume=79&rft.issue=3&rft.spage=495&rft_id=info:doi/10.1253%2Fcircj.CJ-15-0138&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-9843&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-9843&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-9843&client=summon |